Misdiagnosis isn't just inconvenient—it's harmful.
For the more than one million Brazilians living with Alzheimer's disease, diagnosis has long been a matter of clinical judgment shadowed by invasive procedures and uncertain margins. A new blood test, now available through the Dasa network, uses mass spectrometry to detect the protein signatures of Alzheimer's in the bloodstream — offering a less burdensome path toward clarity. It does not replace the physician's eye, but it extends the reach of certainty into cases where the difference between diagnoses can mean the difference between healing and harm.
- Alzheimer's affects 1.2 million Brazilians and kills at a rate of 25 per 100,000 — yet for decades, its most reliable diagnosis required a needle inserted between vertebrae to extract fluid from the spine.
- The blood-brain barrier makes beta-amyloid nearly invisible in the bloodstream, a biological obstacle that long made blood-based testing seem out of reach.
- Mass spectrometry technology now detects those vanishingly small molecular traces, arriving in Brazil just weeks after its U.S. debut through the Dasa hospital and laboratory network.
- The test is not universal — Alzheimer's remains a clinical diagnosis — but it is critical in cases where it must be distinguished from frontotemporal dementia, since Alzheimer's treatments can actively worsen that condition.
- Specialists frame the test as a complement to existing tools, one that spares select patients from costly, contraindicated spinal procedures while sharpening diagnostic precision where it matters most.
Brazil now has access to a blood test that could change how Alzheimer's disease is diagnosed. Arriving through the Dasa hospital and laboratory network shortly after its launch in the United States, the test uses mass spectrometry to detect beta-amyloid — a protein that accumulates in brain tissue years before symptoms appear — directly from a blood sample.
Alzheimer's is the most common form of dementia worldwide. In Brazil, roughly 1.2 million people live with the disease, which accounts for 25 deaths per 100,000 inhabitants. The condition erodes memory and daily function through the progressive degeneration of the central nervous system. Neurologist Rodrigo Carvalho notes that the field is increasingly moving toward classifying Alzheimer's through its biological markers: the buildup of beta-amyloid triggers tau retention, which in turn kills neurons and accelerates decline.
Until now, measuring beta-amyloid reliably meant collecting cerebrospinal fluid through a spinal procedure — expensive, technically demanding, and impossible for patients with certain physical contraindications. The new test sidesteps this by using mass spectrometry, which can isolate and measure molecules even in the minute quantities that cross the blood-brain barrier into the bloodstream.
Still, the test is not a universal screening tool. Alzheimer's diagnosis depends on specialist evaluation, imaging, and clinical context. Its clearest value lies in distinguishing Alzheimer's from frontotemporal dementia — a distinction with real consequences, since treatments for one can worsen the other. As Dasa's medical director Gustavo Campana puts it, the test is not for everyone, but for specific cases where diagnostic confirmation is essential, it offers a less invasive and potentially life-altering answer.
Brazil now has access to a blood test that could reshape how doctors diagnose Alzheimer's disease. The test, which arrived in the country through the Dasa hospital and laboratory network just over a month after its U.S. launch, uses advanced technology to detect a protein marker in the bloodstream—a development that sidesteps the invasiveness and cost of older diagnostic methods.
Alzheimer's remains the most common form of dementia worldwide. In Brazil alone, roughly 1.2 million people live with the disease, and it strikes about 11 percent of the elderly population. The condition destroys the brain's ability to form memories and perform everyday tasks, stemming from degeneration of the central nervous system. The mortality toll is significant: in 2019, Alzheimer's and related dementias accounted for 25 deaths per 100,000 Brazilians.
For decades, diagnosing Alzheimer's has relied on clinical observation—a doctor reviews symptoms, runs imaging tests, and makes a judgment call. But researchers have identified two proteins that appear consistently in Alzheimer's brains: beta-amyloid and tau. Beta-amyloid normally exists on neuron walls, but in Alzheimer's patients, it accumulates in brain tissue years before symptoms emerge. This buildup triggers tau retention, which then kills neurons and sets off the brain's degenerative spiral. Rodrigo Carvalho, a neurologist at DFVNeuro and Hospital Sírio-Libanês, notes that this understanding has shifted how the field thinks about the disease: "The trend is increasingly to classify Alzheimer's based on these altered substances."
Until now, the most reliable way to measure beta-amyloid was through cerebrospinal fluid collection—a procedure in which a doctor inserts a needle between vertebrae to extract fluid from around the brain and spinal cord. Lower beta-amyloid levels in this fluid suggest the protein is trapped in brain tissue, a hallmark of Alzheimer's. But the procedure is expensive, requires a trained physician, and carries contraindications for patients with skin infections or spinal problems that make needle insertion difficult.
The new blood test works on the same principle but overcomes these barriers through mass spectrometry, a technology that separates and measures molecules even when they appear in tiny quantities. The challenge is that beta-amyloid crosses from cerebrospinal fluid into the bloodstream in much smaller amounts—a phenomenon called the blood-brain barrier. A standard blood test would miss these traces. Mass spectrometry doesn't. Gustavo Campana, Dasa's medical director, explains: "It's a technology that allows me to separate different molecules to observe their concentration."
Yet the test is not for everyone. Alzheimer's remains fundamentally a clinical diagnosis, one that depends on a specialist's evaluation alongside imaging and other tests. Magnetic resonance imaging, for instance, can rule out conditions that mimic Alzheimer's, such as stroke. The blood test shines in specific scenarios—particularly when a doctor suspects Alzheimer's but needs to distinguish it from frontotemporal dementia, another neurodegenerative disease. This distinction matters urgently: Alzheimer's treatments can worsen frontotemporal dementia. In such cases, Carvalho says, a precise diagnosis becomes essential to avoid harm.
Campana emphasizes the test's role as a complement, not a replacement: "It's not that everyone needs it, but for some specific cases, diagnostic confirmation is fundamental." For now, the blood test represents a step toward earlier, more accurate detection—and a way to spare patients the discomfort and cost of spinal procedures when a simple blood draw might suffice.
Notable Quotes
The trend is increasingly to classify Alzheimer's based on these altered substances.— Rodrigo Carvalho, neurologist at DFVNeuro and Hospital Sírio-Libanês
It's not that everyone needs it, but for some specific cases, diagnostic confirmation is fundamental.— Gustavo Campana, medical director of Dasa
The Hearth Conversation Another angle on the story
Why does it matter that we can now measure beta-amyloid in blood instead of cerebrospinal fluid?
Because the old way required a needle in your spine. It was expensive, risky for certain patients, and only available in specialized centers. A blood test is something any lab can do.
But you said the protein appears in much smaller amounts in blood. How does that change what we can actually detect?
That's where mass spectrometry comes in. It's sensitive enough to spot those tiny traces. It's like being able to find a specific grain of sand on a beach instead of needing a handful.
If Alzheimer's is still diagnosed clinically, what does this test actually change for a patient?
It removes ambiguity in the cases where it matters most. If someone has memory problems and a doctor isn't sure whether it's Alzheimer's or frontotemporal dementia, this test can answer that question. And that answer determines which drugs you get—or don't get.
You mentioned treatment can make things worse. How?
Frontotemporal dementia damages different brain regions than Alzheimer's does. Drugs that help Alzheimer's patients can accelerate decline in frontotemporal patients. So misdiagnosis isn't just inconvenient—it's harmful.
Who actually needs this test, then?
Not everyone with memory loss. But people whose symptoms are unclear, or where the stakes of getting it wrong are high. It's a tool for precision, not a screening test for the whole population.
What happens next? Does this change how Brazil approaches Alzheimer's?
Slowly. The test is available now through Dasa, but it's not standard care yet. Over time, as doctors see how it helps in those difficult cases, it may become more routine. But that takes years.